Alzamend Neuro Stock Buy Hold or Sell Recommendation
| ALZN Stock | USD 1.26 0.06 5.00% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Alzamend Neuro is 'Strong Sell'. The recommendation algorithm takes into account all of Alzamend Neuro's available fundamental, technical, and predictive indicators you will find on this site.
Check out Alzamend Neuro Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide. In addition, we conduct extensive research on individual companies such as Alzamend and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Alzamend Neuro. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Alzamend |
Execute Alzamend Neuro Buy or Sell Advice
The Alzamend recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Alzamend Neuro. Macroaxis does not own or have any residual interests in Alzamend Neuro or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Alzamend Neuro's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Moves slightly opposite to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Alzamend Neuro Trading Alerts and Improvement Suggestions
| Alzamend Neuro generated a negative expected return over the last 90 days | |
| Alzamend Neuro may become a speculative penny stock | |
| Alzamend Neuro has high historical volatility and very poor performance | |
| Alzamend Neuro has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (9.95 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Alzamend Neuro currently holds about 11.53 M in cash with (8.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.12. | |
| Latest headline from MacroaxisInsider: Acquisition by Mcgrath Lynne Fahey of 25000 shares of Alzamend Neuro at 1.213 subject to Rule 16b-3 |
Alzamend Neuro Returns Distribution Density
The distribution of Alzamend Neuro's historical returns is an attempt to chart the uncertainty of Alzamend Neuro's future price movements. The chart of the probability distribution of Alzamend Neuro daily returns describes the distribution of returns around its average expected value. We use Alzamend Neuro price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Alzamend Neuro returns is essential to provide solid investment advice for Alzamend Neuro.
| Mean Return | -0.38 | Value At Risk | -6.63 | Potential Upside | 5.00 | Standard Deviation | 3.70 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Alzamend Neuro historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Alzamend Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Alzamend Neuro, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Alzamend Neuro back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Rfg Advisory Group, Llc | 2024-09-30 | 0.0 | Virtu Financial Llc | 2024-06-30 | 0.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 0.0 | Susquehanna International Group, Llp | 2024-09-30 | 16.6 K | Bb&t Corp. | 2024-09-30 | 15.5 K | Tower Research Capital Llc | 2024-09-30 | 4.2 K | Blackrock Inc | 2024-09-30 | 4 K | Wells Fargo & Co | 2024-09-30 | 1000 | Corecap Advisors, Llc | 2024-09-30 | 708 | Bank Of America Corp | 2024-09-30 | 105 | Harbor Investment Advisory, Llc | 2024-09-30 | 20.0 |
Alzamend Neuro Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 1.8M | 12.1M | (8.9M) | (4.8M) | (4.3M) | (4.1M) | |
| Net Borrowings | 72.7K | (16.7K) | 2.3M | (58.7K) | (67.5K) | (64.1K) | |
| Net Income | (5.0M) | (12.4M) | (14.9M) | (9.9M) | (9.0M) | (9.4M) | |
| Change To Netincome | 2.4M | 2.5M | 4.4M | 3.6M | 4.1M | 2.5M | |
| End Period Cash Flow | 1.9M | 14.1M | 5.1M | 376.0K | 432.5K | 410.8K | |
| Investments | 105K | 100.9K | (106.5K) | (147.2K) | (132.5K) | (125.9K) | |
| Free Cash Flow | (2.7M) | (6.7M) | (8.9M) | (8.4M) | (7.6M) | (8.0M) | |
| Other Non Cash Items | 454.6K | 8.8K | 1.7M | 714.0 | 642.6 | 610.47 |
Alzamend Neuro Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Alzamend Neuro or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Alzamend Neuro's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Alzamend stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.39 | |
β | Beta against Dow Jones | -0.3 | |
σ | Overall volatility | 3.68 | |
Ir | Information ratio | -0.11 |
Alzamend Neuro Volatility Alert
Alzamend Neuro exhibits very low volatility with skewness of -0.53 and kurtosis of 1.5. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Alzamend Neuro's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Alzamend Neuro's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Alzamend Neuro Fundamentals Vs Peers
Comparing Alzamend Neuro's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Alzamend Neuro's direct or indirect competition across all of the common fundamentals between Alzamend Neuro and the related equities. This way, we can detect undervalued stocks with similar characteristics as Alzamend Neuro or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Alzamend Neuro's fundamental indicators could also be used in its relative valuation, which is a method of valuing Alzamend Neuro by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Alzamend Neuro to competition |
| Fundamentals | Alzamend Neuro | Peer Average |
| Return On Equity | -44.08 | -0.31 |
| Return On Asset | -2.14 | -0.14 |
| Current Valuation | 6.77 M | 16.62 B |
| Shares Outstanding | 5.43 M | 571.82 M |
| Shares Owned By Insiders | 4.55 % | 10.09 % |
| Shares Owned By Institutions | 0.94 % | 39.21 % |
| Number Of Shares Shorted | 62.94 K | 4.71 M |
| Price To Book | 1.82 X | 9.51 X |
| EBITDA | (9.89 M) | 3.9 B |
| Net Income | (9.95 M) | 570.98 M |
| Cash And Equivalents | 11.53 M | 2.7 B |
| Cash Per Share | 0.12 X | 5.01 X |
| Total Debt | 300.71 K | 5.32 B |
| Current Ratio | 11.78 X | 2.16 X |
| Book Value Per Share | (3.77) X | 1.93 K |
| Cash Flow From Operations | (8.27 M) | 971.22 M |
| Short Ratio | 1.03 X | 4.00 X |
| Earnings Per Share | (138.31) X | 3.12 X |
| Target Price | 32.0 | |
| Number Of Employees | 4 | 18.84 K |
| Beta | -0.038 | -0.15 |
| Market Capitalization | 6.85 M | 19.03 B |
| Total Asset | 631.59 K | 29.47 B |
| Retained Earnings | (54.02 M) | 9.33 B |
| Working Capital | (2.77 M) | 1.48 B |
| Net Asset | 631.59 K |
Note: Acquisition by Mcgrath Lynne Fahey of 25000 shares of Alzamend Neuro at 1.213 subject to Rule 16b-3 [view details]
Alzamend Neuro Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Alzamend . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Alzamend Neuro Buy or Sell Advice
When is the right time to buy or sell Alzamend Neuro? Buying financial instruments such as Alzamend Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Alzamend Neuro in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Plastics Thematic Idea Now
Plastics
Companies manufacturing rubber and plastics accessories. The Plastics theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Plastics Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Alzamend Neuro Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.